Haemonetics Co. (HAE) Position Lifted by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC boosted its holdings in Haemonetics Co. (NYSE:HAE) by 229.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 105,554 shares of the medical instruments supplier’s stock after acquiring an additional 73,483 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Haemonetics were worth $12,059,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Lisanti Capital Growth LLC acquired a new position in Haemonetics in the third quarter valued at approximately $2,764,000. Virginia Retirement Systems ET AL acquired a new position in Haemonetics in the third quarter valued at approximately $1,730,000. American Century Companies Inc. lifted its holdings in Haemonetics by 231.1% in the third quarter. American Century Companies Inc. now owns 1,005,784 shares of the medical instruments supplier’s stock valued at $115,243,000 after acquiring an additional 701,976 shares during the last quarter. CIBC Asset Management Inc acquired a new position in Haemonetics in the third quarter valued at approximately $219,000. Finally, Moody Aldrich Partners LLC lifted its holdings in Haemonetics by 18.9% in the third quarter. Moody Aldrich Partners LLC now owns 27,421 shares of the medical instruments supplier’s stock valued at $3,142,000 after acquiring an additional 4,355 shares during the last quarter. Hedge funds and other institutional investors own 96.44% of the company’s stock.

HAE has been the topic of a number of recent analyst reports. TheStreet cut Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Barrington Research reissued a “buy” rating and issued a $127.00 target price on shares of Haemonetics in a research report on Friday, October 5th. Morgan Stanley boosted their target price on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 7th. Finally, Zacks Investment Research raised Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price on the stock in a research report on Friday, October 12th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $113.20.

Shares of NYSE HAE opened at $111.61 on Friday. The company has a market capitalization of $5.95 billion, a price-to-earnings ratio of 59.68, a PEG ratio of 3.67 and a beta of 1.09. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.94 and a current ratio of 2.92. Haemonetics Co. has a 52-week low of $53.74 and a 52-week high of $117.56.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.02. The company had revenue of $241.58 million for the quarter, compared to analyst estimates of $233.44 million. Haemonetics had a return on equity of 16.04% and a net margin of 2.26%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.48 earnings per share. Analysts predict that Haemonetics Co. will post 2.33 earnings per share for the current fiscal year.

In other Haemonetics news, Director Pedro P. Granadillo sold 12,322 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $114.50, for a total value of $1,410,869.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO William P. Mr. Burke sold 841 shares of the business’s stock in a transaction that occurred on Thursday, October 25th. The shares were sold at an average price of $46.76, for a total value of $39,325.16. The disclosure for this sale can be found here. In the last three months, insiders sold 62,653 shares of company stock worth $6,973,391. 1.04% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Haemonetics Co. (HAE) Position Lifted by O Shaughnessy Asset Management LLC” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2018/11/10/haemonetics-co-hae-position-lifted-by-o-shaughnessy-asset-management-llc.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: What is a stock buyback?

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit